CO6331428A2 - Compuestos que comprenden un grupo ciclobutoxi - Google Patents
Compuestos que comprenden un grupo ciclobutoxiInfo
- Publication number
- CO6331428A2 CO6331428A2 CO11001366A CO11001366A CO6331428A2 CO 6331428 A2 CO6331428 A2 CO 6331428A2 CO 11001366 A CO11001366 A CO 11001366A CO 11001366 A CO11001366 A CO 11001366A CO 6331428 A2 CO6331428 A2 CO 6331428A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- seizures
- disorders
- disease
- attention deficit
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010010904 Convulsion Diseases 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 230000037007 arousal Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 206010020765 hypersomnia Diseases 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
Abstract
La presente invención se relaciona con los compuestos de fórmula (I) que comprenden un grupo ciclobutoxi, los procesos para su preparación, composiciones farmacéuticas que comprenden dichos compuestos y su uso como productos farmacéuticos, útiles para el tratamiento y la prevención de enfermedades o estados patológicos del sistema nervioso central, incluida leves -deterioro cognitivo, enfermedad de Alzheimer, el aprendizaje y, trastornos de memoria, trastornos cognitivos, déficit de atención, trastorno de déficit de atención con hiperactividad, la enfermedad de Parkinson, esquizofrenia, demencia, depresión, epilepsia, ataques, convulsiones, trastornos de sueño/ insomnio y la excitación/ vigilancia como hipersomnia y la narcolepsia, el dolor y / o la obesidad.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08104281 | 2008-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6331428A2 true CO6331428A2 (es) | 2011-10-20 |
Family
ID=39929759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11001366A CO6331428A2 (es) | 2008-06-06 | 2011-01-06 | Compuestos que comprenden un grupo ciclobutoxi |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20110098300A1 (es) |
| EP (1) | EP2300426A1 (es) |
| JP (1) | JP2011524344A (es) |
| KR (1) | KR20110033149A (es) |
| CN (1) | CN102083792A (es) |
| AR (1) | AR072051A1 (es) |
| AU (1) | AU2009253961A1 (es) |
| BR (1) | BRPI0912118A2 (es) |
| CA (1) | CA2723626A1 (es) |
| CO (1) | CO6331428A2 (es) |
| EA (1) | EA201001855A1 (es) |
| IL (1) | IL208952A0 (es) |
| MA (1) | MA32374B1 (es) |
| MX (1) | MX2010013405A (es) |
| TW (1) | TW201010995A (es) |
| UY (1) | UY31871A (es) |
| WO (1) | WO2009147149A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| BRPI0712823A2 (pt) | 2006-06-23 | 2012-07-24 | Abbott Lab | derivados de ciclopropil amina como moduladores de receptor de histamina h3 |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| WO2013076590A1 (en) | 2011-11-23 | 2013-05-30 | Oxygen Healthcare Research Pvt. Ltd | Benzothiazine compounds as h3 receptor ligands |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| CN108602809B (zh) * | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10226462A1 (de) * | 2002-06-13 | 2003-12-24 | Aventis Pharma Gmbh | Fluorierte Cycloalkyl-derivatisierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| US7812040B2 (en) * | 2005-06-22 | 2010-10-12 | Pfizer Inc. | Histamine-3 receptor antagonists |
-
2009
- 2009-06-02 AU AU2009253961A patent/AU2009253961A1/en not_active Abandoned
- 2009-06-02 MX MX2010013405A patent/MX2010013405A/es not_active Application Discontinuation
- 2009-06-02 US US12/995,084 patent/US20110098300A1/en not_active Abandoned
- 2009-06-02 JP JP2011512102A patent/JP2011524344A/ja not_active Withdrawn
- 2009-06-02 WO PCT/EP2009/056758 patent/WO2009147149A1/en active Application Filing
- 2009-06-02 CN CN2009801206649A patent/CN102083792A/zh active Pending
- 2009-06-02 KR KR1020107029650A patent/KR20110033149A/ko not_active Application Discontinuation
- 2009-06-02 EP EP09757530A patent/EP2300426A1/en not_active Withdrawn
- 2009-06-02 EA EA201001855A patent/EA201001855A1/ru unknown
- 2009-06-02 BR BRPI0912118A patent/BRPI0912118A2/pt not_active Application Discontinuation
- 2009-06-02 CA CA2723626A patent/CA2723626A1/en not_active Abandoned
- 2009-06-04 TW TW098118528A patent/TW201010995A/zh unknown
- 2009-06-05 UY UY0001031871A patent/UY31871A/es unknown
- 2009-06-05 AR ARP090102018A patent/AR072051A1/es unknown
-
2010
- 2010-10-26 IL IL208952A patent/IL208952A0/en unknown
- 2010-12-03 MA MA33390A patent/MA32374B1/fr unknown
-
2011
- 2011-01-06 CO CO11001366A patent/CO6331428A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009253961A1 (en) | 2009-12-10 |
| BRPI0912118A2 (pt) | 2015-11-03 |
| TW201010995A (en) | 2010-03-16 |
| US20110098300A1 (en) | 2011-04-28 |
| KR20110033149A (ko) | 2011-03-30 |
| AR072051A1 (es) | 2010-08-04 |
| MA32374B1 (fr) | 2011-06-01 |
| IL208952A0 (en) | 2011-01-31 |
| UY31871A (es) | 2010-01-29 |
| EP2300426A1 (en) | 2011-03-30 |
| JP2011524344A (ja) | 2011-09-01 |
| MX2010013405A (es) | 2011-02-15 |
| WO2009147149A1 (en) | 2009-12-10 |
| EA201001855A1 (ru) | 2011-08-30 |
| CN102083792A (zh) | 2011-06-01 |
| CA2723626A1 (en) | 2009-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6331428A2 (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| CL2015000096A1 (es) | Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros | |
| HRP20151334T1 (hr) | Derivat kateholamina koristan u lijeäśenju parkinsonove bolesti | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| CR10208A (es) | Inhibidores de quinasa basados en la hidantoina | |
| CL2008003316A1 (es) | Forma cristalina vi de la agomelatina; procedimientos de preparacion; composicion farmaceutica, util para el tratamiento de estres, ansiedad, depresion mayor, ataques de panico, enfermedad de parkinson, epilepsia, enfermedad de alzheimer. | |
| ECSP13012708A (es) | Compuestos y su uso como inhibidores de bace | |
| DOP2013000194A (es) | Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicos | |
| CL2009000953A1 (es) | Compuestos derivados de 2-imino-3-metil-pirrolo pirimidinona, composicion farmaceutica, util para inhibir la beta-secretasa, destinado al tratamiento de la enfermedad de alzheimer, sindrome de down, parkinson, perdida de la memoria, demencia, accidente cerebrovascular, microgliosis e inflamacion cerebral, glaucoma amiloidosis, diabetes tipo ii, entre otras. | |
| CL2019001539A1 (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| ECSP11011220A (es) | Preparación y aplicaciones terapéuticas de (2s,3r)-n-2-((3-piridinil)metil)-1-azabiciclo[2.2.2] oct-3-il)-3, 5-difluorobenzamida | |
| CL2019000534A1 (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
| NZ573565A (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| NZ592571A (en) | Aryl piperazine and their use as alpha2c antagonists | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| ECSP088876A (es) | Formas de polimorfos de la (2s)-(4e)-n-metil-5-(3-isopropoxipiridin)il]-4-penten-2-amina para el tratamiento de desórdenes del sistema nervioso central | |
| UY30377A1 (es) | Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa | |
| EA201790626A1 (ru) | Макроциклические ингибиторы lrrk2-киназы | |
| AR065431A1 (es) | Formas solidas que comprenden (-) -o-desmetilvenlafaxina y usos de las mismas. | |
| BR112012009121A2 (pt) | Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central | |
| BR112014002859A2 (pt) | purificação pós-processamento para produção de gama-butiro lactona | |
| ECSP10010498A (es) | Procesos para la preparación de derivados de heteroarilo benzofusionados | |
| EA201791367A1 (ru) | Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы | |
| EA201170421A1 (ru) | N-сульфонамидопиразолильные полициклические соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |